Document is current
Any future updates will be listed below
-
Authors
Handle, Florian
Prekovic, Stefan https://orcid.org/0000-0002-7051-9321
Helsen, Christine https://orcid.org/0000-0003-1048-2798
Van den Broeck, Thomas https://orcid.org/0000-0002-7237-7160
Smeets, Elien
Moris, Lisa
Eerlings, Roy
Kharraz, Sarah El
Urbanucci, Alfonso https://orcid.org/0000-0003-2931-3652
Mills, Ian G.
Joniau, Steven https://orcid.org/0000-0003-3195-9890
Attard, Gerhardt
Claessens, Frank https://orcid.org/0000-0002-8676-7709
- License Information
-
More Information
Article History
Received: 1 August 2019
Accepted: 31 August 2019
First Online: 24 September 2019
Competing Interests
: F.H., S.P., C.H., T.V.D.B., E.S., L.M., R.E., S.E.K., A.U., I.G.M., S.J., and F.C. declare no competing interests in relation to this study. G.A. is on the ICR list of rewards to inventors for abiraterone and has received honoraria, consulting fees, travel support or grant support from Abbott Laboratories, Arno Therapeutics, Astellas, AstraZeneca, Bayer Healthcare Pharmaceuticals, Essa Pharmaceuticals, Genentech, Innocrin Pharma, Ipsen, Janssen, Millennium Pharmaceuticals, Novartis, Pfizer, Roche/Ventana, Sanofi-Aventis, Takeda and Veridex.
